A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia

NCT01773408 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelogenous Leukemia, Acute

Interventions

DRUG: RO5503781 MBP
DRUG: RO5503781 SDP
DRUG: Idarubicin
DRUG: Daunorubicin
DRUG: Cytarabine

Sponsor

Hoffmann-La Roche